Latest Headlines

Latest Headlines

Glaxo socks more cash into immunotherapy bet

Last year, GlaxoSmithKline traded away most of its cancer assets to Novartis in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune.

GlaxoSmithKline up-sizes its bet on Adaptimmune, racing forward with a cancer immunotherapy

GlaxoSmithKline, working with Adaptimmune on therapies that use the body's machinery to fight cancer, is sweetening the deal for its partner, promising more cash to accelerate development of a promising treatment for soft tissue sarcoma.

Backed by J&J; and Glaxo, veteran VC group splits from Index, unveils $227M fund

The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.

Pfizer, GSK, AZ and BMS join digital drug design drive to weed out nonviable molecules

A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.

UPDATED: Private clinics seeing shortage of GSK's Bexsero in U.K.

GlaxoSmithKline has been experiencing a high demand for its meningitis B vaccine Bexsero that has led to a shortage of doses for U.K. private clinics outside of the country's National Health Service.

Another legal test for U.S. in case of Chinese scientists accused of stealing GSK secrets

Science Insider has cautioned that a federal indictment against Yu Xue and Lucy Xi and three associates for allegedly stealing trade secrets from GlaxoSmithKline in the U.S. related to work on an anti-HER3 antibody may test prosecutors' ability to get a conviction.

Zika outbreak triggers R&D; attention from pharma, governments

As the Zika virus continues to grab headlines and its spread threatens, governments and industry are urgently committing resources and analyzing vaccine development options.

Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times reports, and fund officials are leaning on Chairman Philip Hampton to shake up management.

GSK, AstraZeneca and J&J; back $57M effort to springboard university drug research

Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at spinning out new therapies into the global pipeline.

GSK scientists accused of data theft in low-tech cybercrime case

Discussions about the threat of cybercrime typically invoke images of armies of hackers whose sole task is to steal data from corporations based across the globe. Yet, as GlaxoSmithKline is now finding out, when solid allegations of cyber-espionage surface a more mundane image of an insider armed with just an email account and a thumb drive emerges.